Leiomyosarcoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Leiomyosarcoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ This clinical trial studies a treatment for soft tissue sarcoma, a type of cancer that develops in soft tissues like muscles and fat. The study focuses on patients whose cancer has spread to other parts of the body (metastatic) or who did not respond well to previous treatments. The trial compares two treatment approaches: one using only trabectedin (a chemotherapy medication) and another combining trabectedin with tTF-NGR (an experimental drug).

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

]]> Study Comparing Trabectedin and Gemcitabine for Patients with Advanced or Metastatic Leiomyosarcoma After Chemotherapy https://clinicaltrials.eu/trial/study-comparing-trabectedin-and-gemcitabine-for-patients-with-advanced-or-metastatic-leiomyosarcoma-after-chemotherapy/ Wed, 29 Apr 2026 14:28:39 +0000 https://clinicaltrials.eu/trial/study-comparing-trabectedin-and-gemcitabine-for-patients-with-advanced-or-metastatic-leiomyosarcoma-after-chemotherapy/ This clinical trial is focused on studying a type of cancer called leiomyosarcoma, which can either spread to other parts of the body (metastatic) or grow in a specific area (locally advanced). The study is comparing two treatments: Trabectedin and Gemcitabine. Both medications are given as a solution through a vein, known as an infusion. The purpose of the study is to compare how well these treatments work in patients who have already received chemotherapy based on a drug called anthracycline.

Participants in the study will receive either Trabectedin or Gemcitabine. The study will observe how the cancer responds to these treatments over time. The main focus is on the growth modulation index (GMI), which is a way to measure how the cancer’s growth is affected by the treatment. A GMI greater than 1.33 is considered a positive sign in this type of study. The study will also look at other factors, such as how long patients live, how long they live without the cancer getting worse, and how safe and tolerable the treatments are.

The study will continue for a period of time, during which patients will be monitored regularly to assess the effectiveness and safety of the treatments. The goal is to gather information that could help improve treatment options for patients with advanced leiomyosarcoma. This study is part of ongoing research to find better ways to manage and treat this type of cancer.

]]> Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma https://clinicaltrials.eu/trial/study-of-lurbinectedin-and-doxorubicin-for-first-line-treatment-in-patients-with-metastatic-leiomyosarcoma/ Wed, 29 Apr 2026 14:26:27 +0000 https://clinicaltrials.eu/trial/study-of-lurbinectedin-and-doxorubicin-for-first-line-treatment-in-patients-with-metastatic-leiomyosarcoma/ This clinical trial is focused on studying a type of cancer called metastatic leiomyosarcoma, which is a cancer that starts in smooth muscle tissue and has spread to other parts of the body. The study is testing a new treatment combination to see if it can help patients with this condition. The treatment being studied includes a drug called lurbinectedin, which is being tested in combination with another drug called doxorubicin hydrochloride. Doxorubicin hydrochloride is already used in cancer treatment, and this study aims to find out if adding lurbinectedin can improve outcomes for patients.

The purpose of the study is to determine if the combination of lurbinectedin and doxorubicin hydrochloride can help patients live longer without their cancer getting worse, compared to using doxorubicin hydrochloride alone. Patients participating in the study will receive these medications through an intravenous (IV) infusion, which means the drugs are given directly into a vein. The study will compare the effects of the combination treatment to the effects of doxorubicin hydrochloride alone, to see which is more effective as a first-line treatment for metastatic leiomyosarcoma.

Participants in the study will be randomly assigned to receive either the combination of lurbinectedin and doxorubicin hydrochloride or doxorubicin hydrochloride alone. The study will be conducted over a period of time, and patients will be monitored to see how their cancer responds to the treatment. The study will also look at the safety of the treatments and any side effects that may occur. This research is important to help find better ways to treat metastatic leiomyosarcoma and improve the quality of life for patients with this condition.

]]>